Characterizing Real-World Functional Outcomes in Patients With Geographic Atrophy: An IRIS Registry Analysis
July 15, 2022 at 10:14 am EDT
Share
Characterizing Real-World Functional
Outcomes in Patients With Geographic
Atrophy: An IRIS Registry Analysis
Durga Borkar, Theodore Leng, Meghan Hatfield, Sonya Li, Mark Gallivan, Preeti Joshi, Alex McKeown
July 15, 2022
40th Annual Meeting of the American Society of Retina Specialists, NY
Financial disclosures
Durga Borkar has the following financial interests or relationships to disclose:
Consulting Fees: Allergan, Glaukos, Regeneron
This study was funded by Apellis Pharmaceuticals
2
Introduction
GA accounts for one-third of the cases of late AMD
Including 20% of cases of severe vision loss1
GA significantly impairs visual function and QoL2
Real-worlddata on correlations between GA progression and functional decline are lacking
We performed a retrospective cohort analysis of patient notes to assess the feasibility of quantifying VR-QoL and PROs in GA
Emphasis was placed on social, functional, and mobility-related outcomes
AMD=age-related macular degeneration; GA=geographic atrophy; PRO=patient-reported outcome; QoL=quality of life; VR-QoL=vision-related quality of life.
3
1. Biarnés M et al. Optom Vis Sci. 2011;88:881-9; 2. Sarda SP et al. Clin Ophthalmol. 2021;15:4629-44.
Part 1. Keyword objective and methodology
Part 1 - Keyword objective: From clinical notesa of patients with GA, determine clinically and potentially contextually relevant keywords associated with social, mobility, and other activity/QoL endpoints
Cohort 1
Newly diagnosed GA
CohortCohort2 2
(PrevalevalentGA,GA, 3-yr follow3-yrfollow-up)-up
First GA diagnosis occurred in 2019
Captured notes associated with initial GA diagnosis date
First GA diagnosis in 2016
Must have ≥3 yrs of follow-up
Captured notes associated with a GA diagnosis at 3-yrs of follow-up
Random sample of 100 notes evaluated
Endpoints
1. Keyword prevalence
2. Context matches
Random sample of 100 notes evaluated
aObtained from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), a real-world electronic health record dataset.
4
GA=geographic atrophy; QoL=quality of life; yr=year.
Keywords
Functional
Driving
Night
Car
Reading
Book
Low Vision
ADL
Face
Fine Print
We searched across all clinical notes (i.e., any text field which is completed), looking at the note on the day of GA diagnosis for Cohort 1, and note with a GA diagnosis after year 3 of follow-up for Cohort 2
Social
Depression
Anxiety
Sad
Autonomy
Independence
Mobility
Disability
Mobility
Rehab
Caregiver
Other
Limited
ADL=activity of daily living; GA=geographic atrophy.
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Apellis Pharmaceuticals Inc. published this content on 15 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 July 2022 14:13:06 UTC.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Companyâs approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
APELLIS PHARMACEUTICALS, INC. 
